insights_auto
Outlook: 100.0% bullish·0.0% bearish
Go to analysischevron_right
A1SN34:BVMF
Ascendis Pharma A/S Bdr
R$95.22
0.00%
(0.00) 1D
Nov 9, 5:28:26 PM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1SN34...
Mkt. cap
17.95B
Avg. vol.
14.00
Volume
0.00
52-wk high
R$95.22
52-wk low
R$70.00
Shares outstanding
62.38M
No. of employees
1K
Mkt. cap
17.95B
Avg. vol.
14.00
Volume
0.00
52-wk high
R$95.22
52-wk low
R$70.00
Shares outstanding
62.38M
No. of employees
1K
News stories
From web sources and news partners
TradingView
·
1 day ago
ASND: Three marketed products underpin €5B revenue ambition by 2030 and €10B by 2035
Investing.com
·
1 day ago
Ascendis Pharma at Jefferies Global Healthcare Conference: growth plan widens
About Ascendis Pharma A/S Bdr
CEO-
Employees1.19K
Founded2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteascendispharma.com
Last report
Nov 12, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (EUR)
- GAAP EPS / Est. (EUR)
€1.71 / €1.65
+3.64%beat
arrow_upward
Revenue / Est. (EUR)
369.66M / 366.36M
+0.90%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in EUR | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 247.50M | 246.60M | 339.28M | 369.66M |
Cost of goods sold | 23.60M | 17.52M | 27.66M | 28.31M |
Cost of revenue | 23.60M | 17.52M | 27.66M | 28.31M |
Research and development expenses | 82.20M | 59.04M | 75.89M | 69.92M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 139.31M | 145.23M | 173.34M | 146.84M |
Operating expense | 221.51M | 204.27M | 91.16M | 216.77M |
Total operating expenses | 245.11M | 221.79M | 118.82M | 245.08M |
Operating income | 2.39M | 24.81M | 220.46M | 124.58M |
Other non operating income | -105.57M | - | - | - |
EBT including unusual items | -26.70M | -48.18M | 230.09M | 113.37M |
EBT excluding unusual items | -34.21M | -48.18M | 230.09M | 113.37M |
Income tax expense | 6.86M | -677.52M | 23.12M | 39.40M |
Effective tax rate | -25.68% | 1,406.31% | 10.05% | 34.75% |
Other operating expenses | - | - | -158.07M | - |
Net income | -33.56M | 629.34M | 206.97M | 73.97M |
Net profit margin | -13.56% | 255.21% | 61.00% | 20.01% |
Earnings per share | -0.55 | 0.27 | 0.90 | 1.71 |
Interest and investment income | 64.06M | 4.52M | 19.96M | 7.71M |
Interest expense | -74.65M | -67.26M | -14.17M | -12.04M |
Net interest expenses | -10.59M | -62.74M | 5.79M | -4.34M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 3.60M | 29.03M | 225.03M | 129.22M |
Gain or loss from assets sale | - | - | 21.00K | - |
Upcoming events